Which infectious disease drugs go off patent, and when?
2 blockbuster infectious disease drugs with $17.1B in 2025 worldwide sales lose US exclusivity between 2025 and 2037, led by Biktarvy (Gilead, $14.3B). The biggest single year is 2036, with $14.3B.
2025 worldwide sales of each drug, placed in the year its first US generic or biosimilar can launch. Select a year for every drug going off patent that year.
| Drug | Company | US LOE | 2025 sales | Date basis | US copies | Medicare price |
|---|---|---|---|---|---|---|
| Descovy | Gilead | 2031 | $2.8B | Company guidance | Approved, waiting to launch | – |
| Biktarvy | Gilead | 2036 | $14.3B | Settlement / court date | Filed with the FDA | 2028 · pending |
Sorted by the year US exclusivity ends. Each drug's page has the sources.
| Company | Drugs | 2025 revenue from them | Share of company |
|---|---|---|---|
| Gilead | Descovy and Biktarvy | $17.1B | 58% |
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.
Biktarvy (2028, price pending) was selected for Medicare price negotiation. See every negotiated Medicare price →